Abbott (ABT) Declares $0.36 Quarterly Dividend; 1.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abbott (ABT) Reports FreeStyle Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes
June 15, 2020 7:06 AM EDTAbbott (NYSE: ABT) announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes. This is the only iCGM system with optional real-time alarms that measures glucose levels every minute, meeting the highest level of accuracy standards5 over 14 days, including superior day one1 accuracy compared to the other iCGM and excellent accuracy and alarm performance at low end glucose levels.6 With a 14-day wear time, the FreeStyle Libre 2 system is the longest-lasting,... More
Europe sets sights on dud antibody tests amid COVID-19 free-for-all
June 11, 2020 2:05 AM EDTBy Francesco Guarascio
BRUSSELS (Reuters) - The market for COVID-19 antibody tests is red-hot. It has ballooned in a matter of months as hundreds of products flood the world for people who want to find out whether they've already had the virus.
The problem is, some of them don't work properly.
As a result, European authorities aim to tighten regulation of the new sector, to weed out tests that give consistently inaccurate results and crack down on companies that make false claims, three sources familiar with the plans told Reuters.
Much is on the... More
